牛津疫苗继“无法证明对老人有效”之后又遭遇重大挫折，这个是目前世界上预定量最大的疫苗。所以给疫苗解决新冠前景蒙上了很厚的阴影。 Oxford/AstraZeneca Covid jab far less effective against S African strain, study shows
https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36 The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study due to be published on Monday. Although none of the more than 2,000 patients in the study died or was hospitalised, the findings could complicate the race to roll out vaccines as new strains emerge. In both the human trials and tests on the blood of those vaccinated, the jab showed significantly reduced efficacy against the 501Y.V2 viral variant, which is dominant in South Africa, according to the randomised, double-blind study seen by the Financial Times. “A two-dose regimen of [the vaccine] did not show protection against mild-moderate Covid-19 due to [the South African variant]”, the study says, adding that efficacy against severe Covid-19, hospitalisations and deaths was not yet determined. The so-called Kent variant — which Oxford university said on Friday was just as susceptible to the vaccine as older variants of the virus — has now acquired the E484K mutation, which is present in the variants fuelling Covid-19 surges in Brazil and South Africa. There are caveats to the study, which has not yet been peer-reviewed, as the sample sizes were relatively small. The study, led by South Africa’s University of the Witwatersrand and Oxford university, enrolled 2,026 HIV negative individuals, with a median age of 31. Half the group was given at least one dose of placebo, with the other half receiving at least one dose of vaccine. Tulio de Oliveira, who heads the Network for Genomic Surveillance in South Africa, told the Financial Times the findings were a “wake-up call to control the virus and increase the response to Covid-19 in the world”. Health authorities worldwide hope vaccines will reduce or completely eliminate the burden of hospitalisation, which would allow for lockdowns to be eased. While important, it is relatively less urgent to avert symptomatic, but milder, infection that does not progress to hospitalisation. Any setback for the efficacy of the Oxford/AstraZeneca vaccine would be particularly crucial for the developing world, as the partners are producing billions of doses on a non-profit basis during the pandemic. The vaccine still appears to be fully effective in preventing hospitalisation and death caused by other variants of coronavirus, according to data from other studies. AstraZeneca declined to comment and referred questions to Oxford. Oxford declined to comment on the results of the study, saying only that it was working with partners across the globe, including in South Africa, to evaluate the effects of new variants on the first generation of its Covid vaccine. “Oxford is working with AstraZeneca to optimise the pipeline required for a strain change should one become necessary,” the university said. “This is the same issue that is faced by all of the vaccine developers, and we will continue to monitor the emergence of new variants that arise in readiness for a future strain change.” The University of the Witwatersrand did not respond to requests for comment. South Africa’s Department of Health did not immediately respond to a request for comment. Recommended Coronavirus pandemic More infectious coronavirus variants will emerge, disease expert predicts While all Covid-19 vaccines so far have largely held up against the B.1.1.7 variant that emerged in the UK, the strain that originated in South Africa has been more worrying. Both Johnson & Johnson and Novavax have said their vaccines were less effective against the strain in clinical trials conducted in South Africa. In trials, both vaccines offered complete protection against severe disease and death in relation to Covid-19. Moderna has said it will test a booster shot and a reformulated vaccine to target the South African variant, after studies showed its vaccine was significantly less effective. BioNTech/Pfizer said their vaccine was slightly less effective in a lab study using a pseudovirus with some mutations from the 501Y.V2 variant, but have not published results of tests against the variant itself. The 501Y.V2 variant, dominant in South Africa, has recently been discovered in countries all over the world, including the US and the UK. South Africa took delivery of 1m doses of the AstraZeneca vaccine last week, the first Covid-19 vaccines to arrive in the country, as part of a 1.5m dose order from India’s Serum Institute.
All 78 residents at a nursing home in central Spain have tested positive for Covid-19 after being given their first dose of the Pfizer-BioNTech vaccine, and at least seven people have died, staff confirmed on Monday. https://www.rt.com/news/514303-deaths-pfizer-vaccine-covid-spain/ 哪里走样了？靠谱吧？ 抓紧洗吧！ 回头我来检查作业。
All 78 residents at a nursing home in central Spain have tested positive for Covid-19 after being given their first dose of the Pfizer-BioNTech vaccine, and at least seven people have died, staff confirmed on Monday. https://www.rt.com/news/514303-deaths-pfizer-vaccine-covid-spain/ 哪里走样了？靠谱吧？ 抓紧洗吧！ 回头我来检查作业。 大青椒 发表于 2021-02-06 17:42
“On January 13, all residents, including nursing home staff, were vaccinated with the first dose of the Pfizer vaccine, and after six days the first symptoms began to appear in ten of the residents,” they said in a statement. 按理第一针疫苗在两个星期以后开始提供一些保护，在此之前没有防护作用。这个例子还真的不能说明疫苗无效。严格来说，这个案例只能让人怀疑疫苗的副作用。
“On January 13, all residents, including nursing home staff, were vaccinated with the first dose of the Pfizer vaccine, and after six days the first symptoms began to appear in ten of the residents,” they said in a statement. 按理第一针疫苗在两个星期以后开始提供一些保护，在此之前没有防护作用。这个例子还真的不能说明疫苗无效。严格来说，这个案例只能让人怀疑疫苗的副作用。 流水石磨 发表于 2021-02-06 17:55
国药灭活疫苗对南非变种依然有效. https://www.biorxiv.org/content/10.1101/2021.02.01.429069v1.full.pdf 接种志愿者血清对新冠病毒wild type, G614D变种, 和南非501Y变种中和抗体滴度无显著差异. Chinese COVID-19 vaccine effective against South Africa variant by Daily Sabah with Reuters BEIJING Health Feb 04, 2021 1:25 pm GMT+3 [url]https://www.dailysabah.com/life/health/chinese-covid-19-vaccine-effective-against-south-africa-variant[/url]
Oxford/AstraZeneca Covid jab far less effective against S African strain, study shows
https://www.ft.com/content/e9bbd4fe-e6bf-4383-bfd3-be64140a3f36
The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study due to be published on Monday.
Although none of the more than 2,000 patients in the study died or was hospitalised, the findings could complicate the race to roll out vaccines as new strains emerge. In both the human trials and tests on the blood of those vaccinated, the jab showed significantly reduced efficacy against the 501Y.V2 viral variant, which is dominant in South Africa, according to the randomised, double-blind study seen by the Financial Times. “A two-dose regimen of [the vaccine] did not show protection against mild-moderate Covid-19 due to [the South African variant]”, the study says, adding that efficacy against severe Covid-19, hospitalisations and deaths was not yet determined.
The so-called Kent variant — which Oxford university said on Friday was just as susceptible to the vaccine as older variants of the virus — has now acquired the E484K mutation, which is present in the variants fuelling Covid-19 surges in Brazil and South Africa. There are caveats to the study, which has not yet been peer-reviewed, as the sample sizes were relatively small. The study, led by South Africa’s University of the Witwatersrand and Oxford university, enrolled 2,026 HIV negative individuals, with a median age of 31. Half the group was given at least one dose of placebo, with the other half receiving at least one dose of vaccine.
Tulio de Oliveira, who heads the Network for Genomic Surveillance in South Africa, told the Financial Times the findings were a “wake-up call to control the virus and increase the response to Covid-19 in the world”. Health authorities worldwide hope vaccines will reduce or completely eliminate the burden of hospitalisation, which would allow for lockdowns to be eased. While important, it is relatively less urgent to avert symptomatic, but milder, infection that does not progress to hospitalisation. Any setback for the efficacy of the Oxford/AstraZeneca vaccine would be particularly crucial for the developing world, as the partners are producing billions of doses on a non-profit basis during the pandemic. The vaccine still appears to be fully effective in preventing hospitalisation and death caused by other variants of coronavirus, according to data from other studies.
AstraZeneca declined to comment and referred questions to Oxford. Oxford declined to comment on the results of the study, saying only that it was working with partners across the globe, including in South Africa, to evaluate the effects of new variants on the first generation of its Covid vaccine. “Oxford is working with AstraZeneca to optimise the pipeline required for a strain change should one become necessary,” the university said. “This is the same issue that is faced by all of the vaccine developers, and we will continue to monitor the emergence of new variants that arise in readiness for a future strain change.” The University of the Witwatersrand did not respond to requests for comment. South Africa’s Department of Health did not immediately respond to a request for comment. Recommended Coronavirus pandemic More infectious coronavirus variants will emerge, disease expert predicts While all Covid-19 vaccines so far have largely held up against the B.1.1.7 variant that emerged in the UK, the strain that originated in South Africa has been more worrying.
Both Johnson & Johnson and Novavax have said their vaccines were less effective against the strain in clinical trials conducted in South Africa. In trials, both vaccines offered complete protection against severe disease and death in relation to Covid-19. Moderna has said it will test a booster shot and a reformulated vaccine to target the South African variant, after studies showed its vaccine was significantly less effective. BioNTech/Pfizer said their vaccine was slightly less effective in a lab study using a pseudovirus with some mutations from the 501Y.V2 variant, but have not published results of tests against the variant itself.
The 501Y.V2 variant, dominant in South Africa, has recently been discovered in countries all over the world, including the US and the UK. South Africa took delivery of 1m doses of the AstraZeneca vaccine last week, the first Covid-19 vaccines to arrive in the country, as part of a 1.5m dose order from India’s Serum Institute.
牛津疫苗欧洲一些国家暂时没有批准给老人使用，瑞士干脆就否决了。
所以之前有人说能有机会打mrna的该感到庆幸，其它疫苗目前都没那么靠谱，以后轮到普通人打了恐怕没有选择
你发的消息都不是靠谱媒体的，没有英语原文报道信息一般会走样不少
All 78 residents at a nursing home in central Spain have tested positive for Covid-19 after being given their first dose of the Pfizer-BioNTech vaccine, and at least seven people have died, staff confirmed on Monday. https://www.rt.com/news/514303-deaths-pfizer-vaccine-covid-spain/ 哪里走样了？靠谱吧？ 抓紧洗吧！ 回头我来检查作业。
“On January 13, all residents, including nursing home staff, were vaccinated with the first dose of the Pfizer vaccine, and after six days the first symptoms began to appear in ten of the residents,” they said in a statement.
按理第一针疫苗在两个星期以后开始提供一些保护，在此之前没有防护作用。这个例子还真的不能说明疫苗无效。严格来说，这个案例只能让人怀疑疫苗的副作用。
从时间节点看可能打疫苗的时候或者打疫苗之前感染了病毒。
那是JNJ疫苗吧？牛津/AZ疫苗没有美国的数据是不可能交给FDA的，早期trial里面65岁以上的疫苗和安慰剂各一个感染，完全看不出是否有效，怎么可能获批？
可能是我记错了。。。。。。希望牛津能研究出对付变异的疫苗。。。。。
蛋不是你这么样扯的，我从来只转载有信誉的媒体的新闻-基本都是花钱才能看的， 而且我老也从未造谣过中国疫苗，跟你这种每天担心政府抓你家娃打mRNA的迫害妄想症不一样。 https://m.huaren.us/showtopic.html?topicid=2629123
理解能力有误真是没办法 这句说抓娃出来打疫苗好想你自己说的吧 你们组的任务是专门过来洗地辉瑞疫苗的吧
在美国还要看新华社的消息非蠢既坏
你知道你们五毛粉蛆的最基本问题是啥吗；“无知”和兴高采烈的被碉堡”愚民“
牛津疫苗的T细胞免疫挺好的，就算体液免疫没用了，理论上防止重症应该也没什么问题。不过这东西没做临床实验谁都不敢把话说死，现在我感觉这个疫苗在美国的前途很成问题了。。。
早说了在美国没人强迫你打疫苗，一天到晚造谣说你不信任mRNA是怕在你家娃身上打， 这不是迫害妄想症是啥？ 另外你claim你老公得过新冠，其实没准你和你娃身上都有抗体了，完全没必要担心嘛！
那句话是抓了娃去打？ 关注mrna负面新闻有什么问题？ 是你阅读理解有问题？今年你们台湾funding那么少 都气急败坏了啊
照照镜子瞧你这幅语无伦次的丑样，我老直接把你以前的帖翻出来甩你脸上感觉如何？
这根本是故意引导的恶意新闻，最早来自今日俄罗斯，今日俄罗斯引自西班牙艾菲通信社，但艾菲通信社并没有这条新闻，其实是在西班牙先锋报上。新华社和环球引用这条新闻也没搞清楚到底出处是哪里。七个老人只有一个是事后检验出只有一个有抗体阳性，其他还未产生抗体。就这样一条新闻被名声一直不怎么地的今日俄罗斯发现，故意不提具体的情况不做调查报道误导让人以为是疫苗无效导致死亡。知乎还是有认真负责的人，自己搜西班牙养老院，这个新闻下第一高赞就是作者抽丝剥茧发现的
感觉轮子气急败坏了 哈哈哈
要点脸吧 所有人都知道：只要唱衰国外疫苗，必定有你。皮厚程度简直叹为观止
不要和精神病吵架
早屏蔽这货了， 清净了不少
我也没少说中国不好 你去翻翻 不要眼虾挑着便宜的说 15%的涨幅 你怎么得到的 去年每套上海房子都涨了20%+ 美国30-50%涨幅难道不用交地税 你哪里看到过上海的房子交地税？？ 为啥留在美国一定要说美国好 老二不举的也没见人挥刀自宫 也不有女的凑合着用了吗 是你和市场反着说 自己写的股票的帖子都是错的 还在那里瞎显摆
这个大青椒不是误看新华社的新闻，他就是彻头彻底的五毛，从他发的多次贴几乎每个贴都是明显带任务的五毛，我看到他发一次就要打脸他一次。我另外一个回帖已经说了，西班牙养老院事件就是新华社和环球网搬的另外一个假新闻基地今日俄罗斯的特意加工过的新闻，做新闻真假混淆在一起炮制出来的，当然丢人的是新华社，不查实就转载二手假新闻
大多数时候互联网是有记忆的。尤其是中国以外地区的互联网。你一共发了两屏的主题。2018年好些都删掉了。
强生疫苗和牛津疫苗都是腺病毒疫苗，应该结果也是一样，但理论上T细胞免疫能支持多久？
现在BBC的说法是牛津疫苗对南非变种的轻症没什么区别，对重症还是有一定效果的。所以认为牛津疫苗不会降低南非变种的阳性数量，但是可能对住院数量和死亡数量有一定的降低作用。
再说一遍 其实这些信息研究人员和英国政府是互相通气对。英国政府前一阵对南非采取非常激进的封锁手段，计划引入对南非变种流行的地方归国的公民强制宾馆隔离，以及说“疫苗可能效果打折扣”的那些新闻都是吹风通气。了解英国政府的都知道，他们吹风的时候，肯定是风暴要来了。。。
T细胞免疫比体液免疫要持久。
牛津疫苗和现在的四个美国疫苗最大的区别在于spike protein不一样，所以结果还真未必一样。JNJ, Novavax, Pfizer, Moderna都用了一个S-2p修饰让spike protein的构型更加稳定，现在看来这个修饰可能让疫苗产生了比自然感染更全面的抗体。
今天cnn说牛津又在开发针对南非变异的boost shot了，今年秋天出来
造谣有意思吗，没人求你打
[url]https://markets.businessinsider.com/amp/news/moderna-ceo-sold-million-stock-company-emergency-use-vaccine-filing-2020-11-1029830266[/url]
[url]https://www.cnbc.com/amp/2021/01/22/cdc-changes-covid-vaccine-guidance-to-ok-mixing-pfizer-and-moderna-shots-in-exceptional-si.html[/url]
这种骚操作 不看新闻 真的不知道 普通人真的没法脑洞大开
国药灭活疫苗对南非变种依然有效.
https://www.biorxiv.org/content/10.1101/2021.02.01.429069v1.full.pdf
接种志愿者血清对新冠病毒wild type, G614D变种, 和南非501Y变种中和抗体滴度无显著差异.
Chinese COVID-19 vaccine effective against South Africa variant by Daily Sabah with Reuters BEIJING Health Feb 04, 2021 1:25 pm GMT+3 [url]https://www.dailysabah.com/life/health/chinese-covid-19-vaccine-effective-against-south-africa-variant[/url]
早把它屏蔽了 神经病一个
兼听则明.
选择不看国内媒体, 只看biased西媒, 所以才会认知偏差越来越严重.
我没说混着打疫苗没用 因为两个都是mrna 原理一样 但是我还是觉得很奇怪 质疑一下有什么问题？？只能说明researcher也不清楚吧 我觉得他们可能高估了mrna作用